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Belsomra®: A Novel Dual Orexin Receptor Antagonist for the
Treatment of Insomnia
Shane Bogusz, Steven Blake, Michaela Wolford, Victoria Cho, Manoranjan D'Souza, M.D., Ph.D.

This knowledge-based activity is targeted for all pharmacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

ACPE Universal Activity Number (UAN): 0048-0000-16-005-HOl-P
To complete the continuing education program and receive
credit, please go to www.raabecollegeofpharmacy.org/PAW/.

Objectives
After completion of this program, the reader should be able to:
1. List medications currently approved for treatment of
insomnia.
2. Enumerate the limitations of benzodiazepines and
non-benzodiazepines for insomnia treatment.
3. Describe the mechanism of action of suvorexant.
4. List the major adverse effects of suvorexant.
5. Describe the role of the pharmacist in counseling and
managing patients on suvorexant therapy.
Abstract
'Insomnia is a disease state characterized by a persistent difficulty in falling asleep, and results in enormous health-related
and economic costs to both the individual and society. Sever.al medications are currently available for the treatment of
insomnia; however, these medications are associated with
several limitations including anterograde amnesia, dependence, withdrawal symptoms upon stopping the medication
:and rebound insomnia. The U.S. Food and Drug Administra:tion recently approved suvorexant (Belsomra®) as a treatment for insomnia. Suvorexant is a first-in-class dual orexin
receptor antagonist for the treatment of insomnia. This review will first describe the Diagnostic and Statistical Manual
of Mental Disorders (DSM-5) criteria used for diagnosing
·insomnia and current treatment options for insomnia and
then will characterize the role of orexin neurons in the pathophysiology of sleep. Subsequently, pivotal clinical trials that
evaluated the safety, efficacy and adverse effects associated
with suvorexant will be discussed. Finally, the review will
,delineate the role of the pharmacist in managing patients on
suvorexant. Current available_data suggests that suvorexant
possesses superior efficacy compared to placebo and a better
:safety profile compared to alternative insomnia treatments.
1Further study of suvorexant in larger and diverse populations is necessary to confirm existing findings. In particular,
;trials with longer durations, direct comparisons with cur!rently available sleep medications and more participants
:would increase the confidence among prescribers and
healthcare providers and promote the use of suvorexant for
!~r~~~ll!e_!lt of insomni<l_.
1
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Introduction
Insomnia refers to a disease state that involves persistent
difficulty falling asleep and/or frequent awakenings during
sleep. Over 35 percent of the adult population exhibits one or
more symptoms associated with insomnia, with 12 percent
to 20 percent actually demonstrating a symptom profile sufficient for diagnosis of the disorder.1 The lack of restful sleep
may lead to symptoms such as daytime fatigue, daytime
sleepiness, memory or concentration deficits, anxiety, depression, irritability, reduced energy and lack of motivation.
Furthermore, insomnia is associated with changes in mood,
poor job performance, disturbed personal relationships and
difficulty in carrying out daily activities. Ozminkowski and
colleagues have estimated that insomnia results in an enormous economic loss to society of approximately $30 billion
per year, mostly through reduced productivity and absenteeism.z Thus, effective insomnia treatments could not only
improve quality of life via symptom relief but also have
tremendous economic benefits to society.
Several treatment options are available for the treatment of
insomnia; however, adverse effects associated with these
treatment options make the management of insomnia challenging. Recently, suvorexant (trade name Belsomra®) was
approved by the U.S. Food and Drug Administration (FDA)
on Aug. 13, 2014, as a Schedule IV drug for insomnia.3 Suvorexant is a dual orexin receptor antagonist, and is the first
medication in this class, offering a novel mechanism for the
treatment of insomnia. This article will discuss the role of
orexin neurons in sleep, the mechanism of action of suvorexant, various clinical studies that demonstrate efficacy of
suvorexant, and finally the role of the pharmacist in dispensing and managing patients taking suvorexant. Additionally,
potential challenges and unanswered questions associated
with suvorexant treatment will be discussed.
Insomnia: Diagnosis, Current Treatment Options and
Challenges With Current Treatment
Insomnia can be broadly divided into primary and secondary
insomnia.I The diagnosis of primary insomnia is defined by
the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) as a sleep disturbance that affects sleep quantity or
quality, causes impairment in activities of daily living, occurs
at least three nights per week for at least three months, and
is not due to substance use, other medical conditions and
other sleep-wake disorders. 4 Additionally, insomnia can be
secondary to other medical diseases, may exacerbate other
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disease states or can even render insomniacs susceptible to
other disease states.s The prevalence of insomnia in the population is clustered among patients with one of several risk
factors.1 For example, insomnia is more prevalent in divorced patients than in those who are married or have never
been married. Insomnia is also more commonly present in
females, African-Americans and in patients with depression.
Lower socioeconomic status is also a risk factor for insomnia.
There are a wide range of treatment options available for
insomnia patients. The two primary treatment strategy
groups are cognitive-behavioral therapy (CBT) and pharmacological therapy. These treatment options are often used
effectively in combination. Cognitive-behavioral therapy
most commonly includes behavioral adjustments, such as
having patients maintain a sleep diary, changing specific habits associated with 'pre-sleep behavior, and other priority
changes for the patient.1 Currently, most commonly used
medications for insomnia target the inhibitory neurotransmitter gamma aminobutyric acid (GABA). Broadly, pharmacological agents acting on the GABA receptors can be divided
into benzodiazepines (BZD) such as flurazepam, triazolam,
estazolam, and lorazepam, and non-benzodiazepines (nonBZD) such as zolpidem, eszopiclone, zaleplon, and zopiclone.
In addition to GABA, histamine neurotransmission has been
an important target for insomnia medications. Tricyclic antidepressants such as trazodone, doxepin and pivagabine,
which have significant antihistaminic properties, and antihistamines such as diphenhydramine are sometimes used in the
treatment of insomnia due to their sedative effects. Finally, a
third group of drugs that are useful in insomnia treatment
are anticonvulsants which can act by enhancing GABA neurotransmission or depressing neuronal activity in generaJ.6
Benzodiazepines and non-BZDs are the most common drug
classes used as a product of their efficacy, however, they still
present many challenges in clinical use. In terms of efficacy,
both BZD and non-BZD drugs have been shown to significantly improve acute insomnia as measured by subjective
total sleep time (sTST) (total length of time asleep, as measured by the patient) and time to sleep onset (sTSO) (total
length of time from lying in bed to sleep initiation, as measured by the patient).6 Additionally, the adverse event profiles
of BZD and non-BZD drugs are similar, with symptoms such
as headache, fatigue and dizziness. BZDs are also associated
with a number of serious adverse effects such as anxiety, anterograde amnesia, poor balance associated with an increase
in falls and morning somnolence.1 Patients taking BZDs for
insomnia also have reported abnormal sleep behaviors, such
as sleep-related walking, eating, driving and sexual activity.
Additionally, BZDs and non-BZDs are susceptible to abuse
and dependency as they can produce either withdrawal
symptoms after use or rebound insomnia upon treatment
discontinuation, thus limiting their use for chronic insomnia.
Currently, only eszopiclone (non-BZD) has been approved
for chronic use in insomnia patients.6 Therefore, these concerns with adverse effects, abuse and dependency fostered a
desire to develop a novel insomnia treatment that would
offer patients a superior treatment option.
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Suvorexant: A Novel Medication for Treatment of Insomnia Targeting Orexin Transmission
Suvorexant (Belsomra®) is a dual orexin receptor antagonist
marketed by Merck Sharp & Dohme Corp_7.a The action of
suvorexant is achieved through interaction with a collection
of neurons known as the orexin system, which coordinates
the body's transition from a sleep-state to an alert-state.9
There are approximately 100,000 orexinergic neurons
spread across the brain, but these neurons are located principally in the lateral hypothalamus and lower brainstem
nuclei.10 The role of orexin in the sleep-wake cycle was elucidated by studying narcolepsy patients. Narcolepsy is a state
characterized by excessive daytime sleepiness and intermittent uncontrollable episodes of daytime sleepiness. Narcolepsy patients were found to lack orexigenic neurons or have
low levels of orexin, a neuropeptide. 11 This discovery eventually led to the conclusion that the death of these neurons or
absence of these neuropeptides is a leading cause in the narcolepsy-cataplexy disease state. Consistent with these findings, the knockout of orexin genes in animals resulted in the
development of narcolepsy in animals. The effects of orexin
released by orexigenic neurons is mediated by two receptors: orexin Rl (OX1R) and R2 (OX2R). Both orexin receptors
are G-protein-coupled receptors. Animal studies support the
important role of OX2R over OX1R in the regulation of the
sleep-wake cycle. 12 Binding of orexin to orexin receptors activates the brain's "wake-promoting system."12 Suvorexant
reversibly inhibits both orexin receptors and, thus, promotes
sleep by preventing activation of the wake-promoting system.
Clinical Studies Demonstrating Efficacy of Suvorexant
Several clinical studies have evaluated the efficacy and adverse effect profile of suvorexant. A summary of the trials
discussed in this article can be found in Table 1.
Michelson and colleagues assessed the safety and efficacy of
suvorexant over a one year period, followed by a two month
discontinuation phase. 13 They reported that suvorexant significantly improved sTST, sTSO and other common measures
of sleep quality as compared to placebo over the course of
therapy (P<0.0001). Specifically, a .9.5 minute average reduction in sTSO and a 22.7 minute average increase in sTST
relative to placebo were demonstrated with suvorexant
treatment. Importantly, no effect on mood was demonstrated, and the most common adverse effects were somnolence
(13.2%), fatigue (6.5%), dry mouth (5.0%), dyspepsia (1.9%)
and peripheral edema (1.7%). Abrupt discontinuation of suvorexant was well-tolerated, with rebound insomnia more
predominant in those who were switched from suvorexant to
placebo during the two-month discontinuation study. Additionally, no significant difference was observed between the
suvorexant-suvorexant or suvorexant-placebo group in
patients with withdrawal symptoms. Overall, the trial illustrated that suvorexant was effective in treating insomnia
over the long-term with minimal adverse effects.
Two other phase III, randomized, double-blinded clinical trials, conducted by Herring and colleagues, investigated the
efficacy and safety of suvorexant versus placebo in over
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Table 1. Summary of Major Trials.• 10, 13-15
Michelson D, et aJ.13

Herring WJ, et al.14

Sun H, et aJ.10

Bettica P, et al.15

Study
Design

Phase III, randomized,
double-blinded,
placebo-controlled

Two Phase III, randomized, double-blinded,
placebo-controlled,
parallel-group trials

Randomized, doubleblinded, placebocontrolled, 2-period
cross-over study

Randomized, doubleblinded, placebocontrolled, 4-period
cross-over study

Number of
Patients

781 (522 suvorexant,
259 placebo)

Trial 1: 1021 total (254
suvorexant 20/15 mg; 383
suvorexant 40/30 mg; 384
placebo)
Trial 2: 1009 total (239
suvorexant 20/15 mg; 387
suvorexant 40/30 mg; 383
placebo)

25 total

51 total

Study
Duration

1 year, followed by 2month discontinuation
phase (primary endpoint: relapse prevention)

3 month trials, each with 1
week run-out period
(discontinuation phase) to
assess withdrawal and
rebound insomnia

4 days per period with
7 day washout period.
2 periods total

2 nights per treatment
session with 7 day washout period.
4 periods total

Inclus ion
Criteria

Patients aged 18 years
and older who met
primary insomnia
criteria in DSM-IV

Patients aged 18 years
and older who met
primary insomnia
criteria in DSM-IV

Patients aged 18-85
years with diagnosis of
Chronic Obstructive
Pulmonary Disease
(COPD)

Male patients aged 18-55
years, body weight >SOkg,
body mass index within
18.5-29.9kg/m2, average
bedtime 10pm-12am
5-7 days per week,
average sleep duration of
6.5-8.5 hours over previous 3 months

Exclusion
Criteria

Those who had
confounding
neurological disorders,
unstable medical
disorders, substance
abuse, major affective
or psychotic illness

Those who had other sleep
disorders, confounding
neurologic disorders,
unstable medical
disorders, substance
abuse, major affective or
psychotic psychiatric
illness

Those who used continuous oxygen therapy,
had other respiratory
disorders, or had sleep
disorders other than
insomnia

Those who consumed
medications or beverages
that could interfere with
study treatments, those
with sleep apnea or other
sleep disorders, those not
prepared to meet study
protocol requirements

Dose(s)
Used

40 mg: patients aged
18-64.9 years
30 mg: patients aged
65 years and above

Both trials assessed:
20 mg, 40 mg: patients
aged 18-64 years
15 mg, 30 mg: patients
aged 65 years and above

40 mg: patients aged 18
-64.9 years
30 mg: patients aged 65
years and above

Suvorexant 10 mg or 30
mg
Zolpidem 10 mg

Primary
Endpoint(s)

Assess tolerability and
safety of suvorexant

Change from baseline in
sTST and sTSO at months
1and3

Mean oxygen saturation (spOz) for total
sleep time (TST) on day
4

Change from baseline in
sTST, wake after sleep
onset and latency to
persistent sleep

Secondary
Endpoint(s)

Changes in sTST and
sTSO

Changes from baseline in
sTST and sTSO at week 1

Mean sp02 on day 1 and
in each sleep stage

Effect on REM and nonREM sleep

*Studies listed here utilized the 4th edition of the Diagnostic and Statistical Manual. There is minimal change in definition of
primary insomnia between the 4th and 5th editions (the 5th edition is currently in use).
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2,000 patients.14 The researchers reported improvement in
sTSO, sTST and other sleep measurement endpoints over the
duration of suvorexant treatment, with less than 5 percent of
patients discontinuing use of the drug due to adverse events.
The trial also included a one week, randomized, doubleblinded run-out period to assess withdrawal and rebound
potential of suvorexant. No marked withdrawal or rebound
symptoms were observed in patients after abrupt suvorexant
discontinuation.
Bettica and colleagues compared the efficacy of suvorexant
and zolpidem (a non-BZD) in a randomized, double-blinded,
placebo-controlled trial in adult male volunteers in a simulated noisy environment.ls Suvorexant 10 mg and 30 mg were
both shown to increase sTST by 17 and 31 minutes respectively as compared to 11 minutes by zolpidem. Additionally,
rapid eye movement (REM) sleep was increased with suvorexant treatment and decreased with zolpidem. However,
the trial did demonstrate more frequent side effects after
suvorexant than after zolpidem due to differences in their
pharmacological activity. More studies are needed to compare the efficacy of suvorexant to existing pharmacologic
insomnia treatments.
Although suvorexant has demonstrated efficacy in promoting
sleep maintenance in both healthy subjects and insomnia
patients, its effects are more clear in the latter. 1 0 A 2013 trial
assessed the effects of suvorexant in healthy individuals
without sleep problems. This study reported no electroencephalogram (EEG) improvements consistent with increases
in deep sleep in these individuals, but the study did report
improvements in other sleep measures including "latency to
persistent sleep" (time before overnight sleep was sustained)
and "wake after sleep onset" incidents. In both of these
measures, suvorexant improved sleep quality in patients
without sleep disorders.
In summary, clinical data available to date suggests that suvorexant is an effective sleep-promoting medication with an
adverse effect profile better than currently available medications. Importantly, suvorexant has been shown to produce
minimal withdrawal effects upon terminating use. Based on
these data it is expected that suvorexant will have minimal to
no abuse/dependence potential. However, future clinical
studies directly comparing suvorexant to other currently
used sleep medications and assessing the long-term effects/
abuse potential of suvorexant are required.
Pharmacist's Role in Managing Patients on Suvorexant
Pharmacists have an important role in educating patients on
suvorexant use, side effects and cautions. Suvorexant is a
white powder that is insoluble in water.7 Available in 5, 10,
15 and 20 mg strengths, the tablets should be stored at room
temperature and protected from moisture and light.B The
onset of action of suvorexant is approximately 30 minutes,
and reaches a maximal plasma concentration (Tmax) in
approximately two hours. Therefore, pharmacists should
counsel patients to take suvorexant no more than 30 minutes
before bed. Consumption of a high-fat meal delays the time
taken to reach maximum levels (T max) by about 1.5 hours.
Winter 2016 Volume 7, Issue 1
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However, this does not otherwise affect the overall maximum concentration reached. Therefore, for rapid onset of
action, patients may be advised to avoid taking suvorexant
with or directly after a meal.
The adverse effect profile for suvorexant is fairly limited as
the drug is generally very well-tolerated.13 Unsurprisingly,
trials have documented somnolence and daytime sleepiness/
fatigue.14 Incidence of dry mouth was increased in suvorexant treatment groups relative to placebo as well. Across
the board, adverse effects occurred in a dose-dependent distribution. Furthermore, the long-term effects of suvorexant
are not well understood, as most existing trials have had
short durations.16 Central nervous system (CNS) adverse effects occur at very low frequencies and can include headache,
abnormal dreams, sleep paralysis, mood changes, confusion,
memory loss, hallucinations, somnambulism and suicidal
ideation.17 Pharmacists should inform the patient to contact
their doctor or pharmacist if any of these symptoms occur.
Suvorexant does not require laboratory monitoring, however, prescribers and pharmacists alike should monitor patients for signs of CNS depressant effects that could potentially harm the patient (e.g., operating a motor vehicle while
experiencing daytime somnolence).16 Pharmacists should
also consult the prescriber if the patient is currently taking
any other CNS depressants. Due to their potential for additive effects, doses of CNS depressants and/or suvorexant
should be adjusted.
Pharmacists will want to inform patients that a scheduled
dose should not be taken if alcohol has been consumed that
evening. Additionally, suvorexant should only be taken when
the patient expects to receive at least seven hours of sleep.
Suvorexant is contraindicated in patients with narcolepsy as
suvorexant will exacerbate this condition.7 Lastly, patients
taking high doses of suvorexant (20 mg a day) should be cautioned about operating motorized vehicles the day after due
to a higher risk of daytime somnolence.
Certain populations, such as the elderly, may benefit from
suvorexant use in comparison to first-line therapy.9 Benzodiazepines commonly cause loss of balance and vertigo, contributing to falls. However, suvorexant's mechanism of action
does not cause vertigo; therefore, some detrimental falls in
elderly patients could be avoided. Additionally, obese patients often suffer from insomnia. Interestingly, suvorexant is
cleared more slowly, and achieves higher peak levels in
obese women (BM!> 30 kg/m2) compared to non-obese
women. This may result in increased adverse effects in obese
women compared to non-obese women. B Therefore, suvorexant therapy should be used with caution in obese patients, especially obese women.
Additionally, due to suvorexant's metabolism by cytochrome
P450 (CYP) 3A4 enzymes, it should not be taken concurrently with CYP3A4 inhibitors (e.g., ketoconazole, itraconazole,
clarithromycin) which will decrease clearance, or with
strong CYP3A4 inducers (e.g. rifampin, carbamazepine, phenytoin) which will reduce efficacy. 16 If a patient is unable to
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discontinue treatment with a CYP3A4 inhibitor, suvorexant
should first be introduced at a reduced (5 mg) dose. Suvorexant is also not recommended for use in pregnancy;
while no teratogenicity has be~n documented, suvorexant
use was associated with decreased fetal body weight in animal models.18 Because of the risk of accumulation, suvorexant is also not recommended for patients with severe
hepatic impairment.7

6.

7.
8.

9.

Challenges and Unanswered Questions
Unfortunately, suvorexant is not covered by all insurance
companies. In fact, one pharmacy benefit management company (Catamaran®) has suggested zolpidem as an alternative to suvorexant.19 Without insurance, patients can expect
to pay approximately $10.52 per tablet (regardless of dose).8
This can result in significant financial burden on patients and
can serve as a disincentive for suvorexant as a treatment option.

10.

11.

12.

13.

Due to limited post-marketing research, there are very few
documented and substantiated contraindications to suvorexant use. Future research could provide a more thorough understanding and awareness of potential risk factors
and contraindications associated with suvorexant, as well as
safety and efficacy with long-term use. Furthermore, a greater understanding of when suvorexant is most and least effective would cement suvorexant's role in insomnia treatment
going forward.

14.

15.

Conclusion
Suvorexant (Belsomra®) is a dual orexin receptor antagonist
and is the first drug for insomnia acting via this mechanism.
Findings from clinical studies suggest that suvorexant improves both sleep onset and total sleep time. In comparison
with zolpidem, suvorexant has been found to significantly
increase the quality and duration of sleep. In addition to improved efficacy, suvorexant does not result in withdrawal
symptoms upon its discontinuation, which is commonly observed with many of the current insomnia treatments. However, one caveat is that long-term studies with suvorexant
are currently unavailable. Cost of the medication may also be
a problem for patients, as insurance companies and pharmacy benefit management companies may not include it on
their formularies. In conclusion, suvorexant holds great
promise due to its efficacy in insomnia patients and its potential to overcome some limitations associated with current
first-line medications available for insomnia treatment.
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Assessment Questions
1.

Which of the following is NOT a major adverse effect of
suvorexant?
A. Somnolence
8. Nocturia
C. Fatigue
D. Dry mouth

7. At which receptor does suvorexant act? Does it act as an
agonist or an antagonist at this receptor?
A. Orexin; antagonist
8. Gamma-amino butyric acid (GABA); agonist
C. Orexin; agonist
D. Gamma-amino butyric acid (GABA); antagonist

2.

Which of the following drug classes is NOT a current
treatment option for insomnia?
A. Benzodiazepine
B. Anticonvulsant
C. Tricyclic antidepressant
D. Selective serotonin reuptake inhibitor

8.

Suvorexant displays an onset of action in:
A. 15 minutes
8. 30 minutes
C. One hour
D. Two hours

9.
3.

Which of the following is an advantage of suvorexant
over benzodiazepines?
A. Marked increase in rebound insomnia following
suvorexant treatment as compared to benzodiazepines.
B. No risk of withdrawal symptoms displayed upon
abrupt discontinuation of suvorexant therapy.
C. Marked increase in orexin neuron firing following suvorexant treatment.
D. There is no significant advantage of suvorexant
over benzodiazepines.

Challenges to the use of suvorexant for treatment of insomnia include:
A. The potential for rebound insomnia following
suvorexant therapy.
B. Few documented contraindications exist to suvorexant use.
C. Limited coverage by insurance companies
D. Both B and C.
E. All of the above.

4.

5.

6.

Which of the following patients would be the best candidate for suvorexant therapy?
A. A well-managed insomnia patient who is struggling to afford his diazepam.
B. An insomnia patient who has not experienced an
increase in sleep time from treatment with a
BZD.
C. A patient without insomnia seeking relief from
somnambulism.
D. A narcoleptic patient who struggles to stay
awake at work.
Which of the following medications would be safe to take
in conjunction with suvorexant?
A. Clarithromycin
B. Carbamazepine
C. Diazepam
D. Methenamine
Which of the following counseling points would be appropriate when educating patients about suvorexant?
A. Patients should only take suvorexant if they expect to receive at least seven hours of sleep.
B. Patients taking high doses of suvorexant should
not operate heavy machinery the following day
until they know how the drug affects them.
C. Patients who have consumed alcohol in an evening should still take their scheduled dose.
D. Both A and B.
E. All of the above.
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10. What specific sleep parameter(s) have demonstrated
marked increase(s) following suvorexant treatment?
A. sTST
B. sTSP
C. sTSA
D. sTSS

Ohio Northern University is accredited by the
Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education. This
program is eligible for credit until 2/9/2019.

To complete the continuing education program and receive
credit, please go to www.raabecollegeofpharmacy.org/PAW/
to enter the required information. Please allow two to three
weeks for electronic distribution of your continuing education certificate, which will be sent to your valid email address
in PDF format.
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